{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:13:11Z","timestamp":1783501991156,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2021YFA1300602"],"award-info":[{"award-number":["2021YFA1300602"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472775"],"award-info":[{"award-number":["82472775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230091"],"award-info":[{"award-number":["82230091"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82025026"],"award-info":[{"award-number":["82025026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2024C03160"],"award-info":[{"award-number":["2024C03160"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2023B1212060013"],"award-info":[{"award-number":["2023B1212060013"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2023B1111030006"],"award-info":[{"award-number":["2023B1111030006"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012412"],"award-info":[{"award-number":["2023A1515012412"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515011214"],"award-info":[{"award-number":["2023A1515011214"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ebiom.2026.106323","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:23:54Z","timestamp":1780910634000},"page":"106323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy"],"prefix":"10.1016","volume":"129","author":[{"given":"Yiming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiren","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingliang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beinan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkun","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taobo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-7303","authenticated-orcid":false,"given":"Man-Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ebiom.2026.106323_bib1","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"issue":"10027","key":"10.1016\/j.ebiom.2026.106323_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.ebiom.2026.106323_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ebiom.2026.106323_bib4","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ebiom.2026.106323_bib5","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced Non\u2012Small-Cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106323_bib7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106323_bib8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106323_bib9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.seminoncol.2015.05.011","article-title":"The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment","volume":"42","author":"Gajewski","year":"2015","journal-title":"Semin Oncol"},{"issue":"5795","key":"10.1016\/j.ebiom.2026.106323_bib10","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"7528","key":"10.1016\/j.ebiom.2026.106323_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"7706","key":"10.1016\/j.ebiom.2026.106323_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106323_bib13","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106323_bib14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"issue":"7693","key":"10.1016\/j.ebiom.2026.106323_bib15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"6184","key":"10.1016\/j.ebiom.2026.106323_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106323_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"6257","key":"10.1016\/j.ebiom.2026.106323_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106323_bib21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106323_bib22","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106323_bib23","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106323_bib24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","article-title":"Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer","volume":"55","author":"Ravi","year":"2023","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106323_bib26","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106323_bib27","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106323_bib28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106323_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2021.06.064","article-title":"Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts","volume":"161","author":"Bortolomeazzi","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106323_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106323_bib31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.annonc.2021.06.006","article-title":"TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061","volume":"32","author":"Foote","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2026.106323_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2018.15","article-title":"ImmPort, toward repurposing of open access immunological assay data for translational and clinical research","volume":"5","author":"Bhattacharya","year":"2018","journal-title":"Sci Data"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106323_bib33","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106323_bib34","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41698-022-00286-4","article-title":"Deletions on 9p21 are associated with worse outcomes after anti-PD-1\/PD-L1 monotherapy but not chemoimmunotherapy","volume":"6","author":"Ebot","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib37","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1038\/s41467-021-24240-3","article-title":"Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine","volume":"12","author":"Barekatain","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106323_bib38","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ebiom.2026.106323_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115625","article-title":"Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors\/hnRNP E1 upregulators: design, synthesis and biological evaluation","volume":"258","author":"Chu","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106323_bib40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/onci.19727","article-title":"Targeting the tumor mutanome for personalized vaccination therapy","volume":"1","author":"Kreiter","year":"2012","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2164-15-190","article-title":"Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma","volume":"15","author":"Castle","year":"2014","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ebiom.2026.106323_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","article-title":"TGF-\u03b2 activation and function in immunity","volume":"32","author":"Travis","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cell.2019.12.030","article-title":"Cryo-EM reveals integrin-mediated TGF-\u03b2 activation without release from latent TGF-\u03b2","volume":"180","author":"Campbell","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib44","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/s41467-022-32655-9","article-title":"Specificity of TGF-\u03b21 signal designated by LRRC33 and integrin \u03b1(V)\u03b2(8)","volume":"13","author":"Duan","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib45","first-page":"323","article-title":"Exploring molecular genetics of bladder cancer: lessons learned from mouse models","volume":"5","author":"Ahmad","year":"2012","journal-title":"Dis Model Mech"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106323_bib47","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106323_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115698","article-title":"Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response","volume":"44","author":"Skelly","year":"2025","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106323_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005952","article-title":"Intratumoral IFN-\u03b3 or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine","volume":"11","author":"Tran","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106323_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004022","article-title":"CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy","volume":"10","author":"Xiao","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ebiom.2026.106323_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1102282","article-title":"MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression","volume":"14","author":"Schr\u00f6rs","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.bbrc.2020.02.132","article-title":"Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2022.12.038","article-title":"Human IRF1 governs macrophagic IFN-\u03b3 immunity to mycobacteria","volume":"186","author":"Rosain","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-023-00522-1","article-title":"Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity","volume":"4","author":"Wu","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-025-02256-3","article-title":"Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers","volume":"24","author":"Hyeon","year":"2025","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106323_bib57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajg.2024.02.001","article-title":"The role of THBS1 and PDGFD in the immune microenvironment of Helicobacter pylori-associated gastric cancer","volume":"25","author":"Zhou","year":"2024","journal-title":"Arab J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106323_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiaf174","article-title":"RABEP1 regulates neutrophil migration via endosomal recycling and actin polymerization","volume":"118","author":"Kim","year":"2026","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106323_bib59","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/blood-2008-04-152660","article-title":"Rabaptin-5 regulates receptor expression and functional activation in mast cells","volume":"112","author":"Rios","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib60","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","article-title":"CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells","volume":"15","author":"Bexte","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106323_bib61","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/2159-8290.CD-24-0991","article-title":"Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma","volume":"15","author":"Hugaboom","year":"2025","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1189\/jlb.1011498","article-title":"K12\/SECTM1, an interferon-\u03b3 regulated molecule, synergizes with CD28 to costimulate human T cell proliferation","volume":"91","author":"Wang","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106323_bib63","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.bbagen.2011.06.020","article-title":"The T\/NK cell co-stimulatory molecule SECTM1 is an IFN \"early response gene\" that is negatively regulated by LPS in human monocytic cells","volume":"1810","author":"Huyton","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"25","key":"10.1016\/j.ebiom.2026.106323_bib64","article-title":"Immunotyping the tumor microenvironment reveals molecular heterogeneity for personalized immunotherapy in cancer","volume":"12","author":"Zeng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"10.1016\/j.ebiom.2026.106323_bib66","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106323_bib67","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106323_bib68","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106323_bib69","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","article-title":"Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy","volume":"11","author":"Pelly","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106323_bib70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106323_bib71","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41551-025-01380-1","article-title":"Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading","volume":"9","author":"Qdaisat","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib72","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106323_bib73","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106323_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102283","article-title":"Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma","volume":"35","author":"Gr\u00fctzner","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106323_bib75","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106323_bib76","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/cancers14010066","article-title":"HDAC inhibition to prime immune checkpoint inhibitors","volume":"14","author":"Borcoman","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106323_bib77","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.it.2020.08.010","article-title":"Overcoming immune checkpoint blockade resistance via EZH2 inhibition","volume":"41","author":"Kim","year":"2020","journal-title":"Trends Immunol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:13:17Z","timestamp":1783498397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426002057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":77,"alternative-id":["S2352396426002057"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106323","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106323"}}